Disease · MONDO_0004608
oropharynx cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. oropharynx cancer. Diseases, record MONDO_0004608. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004608
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of oropharynx, malignant neoplasm of junctional region of oropharynx, malignant neoplasm of lateral wall of oropharynx, malignant neoplasm of oropharynx, malignant neoplasm of posterior wall of oropharynx, malignant neoplasm of the oropharynx, malignant oropharyngeal neoplasm, malignant oropharyngeal tumor, malignant oropharyngeal tumour, malignant oropharynx neoplasm, malignant tumor of mesopharynx, malignant tumor of oropharynx, malignant tumor of posterior wall of oropharynx, malignant tumor of the oropharynx, malignant tumour of mesopharynx, malignant tumour of oropharynx, malignant tumour of posterior wall of oropharynx, malignant tumour of the oropharynx, oropharyngeal cancer, oropharyngeal carcinoma, primary malignant neoplasm of lateral wall of oropharynx
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 26 | 26 | 25 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets81
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 6 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| IL2RB | IL-2R beta/gamma | 2 | IL-2R beta/gamma agonist; Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | IL-2R beta/gamma | 2 | IL-2R beta/gamma agonist; Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| TUBA1A | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 81
See all 81 targetsTrials58
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | Phase 3 | 987 | 2020-01-09 | Head and Neck Cancer, Precancerous Condition | CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Phase 2 | 519 | 2022-09-28 | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | CARBOPLATIN, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Phase 2/3 | 384 | 2025-05-02 | Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma | CISPLATIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | Phase 2 | 316 | 2020-08-12 | Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Phase 1/2 | 224 | 2026-03-09 | Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01932697 | Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer | Phase 2 | 81 | 2019-09-18 | Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma | DOCETAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | Phase 2 | 62 | 2021-01-08 | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | CARBOPLATIN, CISPLATIN, FLUOROURACIL, HYDROXYUREA, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | Phase 2 | 57 | 2022-02-28 | Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer | BINTRAFUSP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Phase 1/2 | 51 | 2023-11-18 | Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, PEXIPEPIMUT-S | Its record names the disease | ClinicalTrials.gov |
| NCT01663259 | Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients | Not applicable | 43 | 2020-10-26 | Squamous Cell Carcinoma of the Oropharynx, HPV | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 58
See all 58 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IMRT + Cisplatin vs IMRT + Cetuximab: deaths from any cause | 64 of 406 | 86 of 399 | 805 | NCT01302834 | Trial comparisons |
| IMRT + Cisplatin vs IMRT + Cetuximab: serious adverse events | 177 of 398 | 115 of 394 | 792 | NCT01302834 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: deaths from any cause | 6 of 152 | 6 of 147 | 299 | NCT02254278 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: serious adverse events | 31 of 152 | 11 of 147 | 299 | NCT02254278 | Trial comparisons |
| Cohort A (Intermediate Risk) vs Cohort B (Extranodal Extension): deaths from any cause | 0 of 38 | 1 of 43 | 81 | NCT01932697 | Trial comparisons |
| Cohort A (Intermediate Risk) vs Cohort B (Extranodal Extension): serious adverse events | 5 of 38 | 5 of 43 | 81 | NCT01932697 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials85
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004608
GET https://conductscience.org/api/diseases/v1/MONDO_0004608/drugs?page=2